This indicates that, in addition to the effectiveness of immunotherapy combined with anti-VEGF drugs in HCC, treatments targeting TGF-β and IL-10 may also be combined with immunotherapy in the future to enhance immunotherapeutic efficacy and provide more treatment options for patients. Here, TGFB1 is linked to hepatocellular carcinoma.